S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Omnicell Stock Forecast, Price & News

+0.13 (+0.08 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume188,556 shs
Average Volume303,796 shs
Market Capitalization$6.87 billion
P/E Ratio121.49
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

Omnicell logo

About Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.


See More Headlines

Industry, Sector and Symbol

Electronic computers
Health Care Technology
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$892.21 million
Cash Flow
$3.60 per share
Book Value
$22.87 per share


Net Income
$32.19 million




Market Cap
$6.87 billion
Next Earnings Date
11/2/2021 (Confirmed)

Social Links


Overall MarketRank

1.64 out of 5 stars

Medical Sector

971st out of 1,361 stocks

Electronic Computers Industry

6th out of 11 stocks

Analyst Opinion: 1.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

Is Omnicell a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell
or view top-rated stocks.

What stocks does MarketBeat like better than Omnicell?

Wall Street analysts have given Omnicell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Omnicell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Omnicell

How can I listen to Omnicell's earnings call?

Omnicell will be holding an earnings conference call on Tuesday, November 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings data on Thursday, July, 29th. The company reported $0.97 EPS for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.42. The company had revenue of $272.74 million for the quarter, compared to analysts' expectations of $267.20 million. Omnicell had a net margin of 6.05% and a trailing twelve-month return on equity of 11.06%.
View Omnicell's earnings history

How has Omnicell's stock price been impacted by Coronavirus?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OMCL stock has increased by 104.0% and is now trading at $157.94.
View which stocks have been most impacted by COVID-19

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of $3.650-$3.750 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.590. The company issued revenue guidance of $1.10 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion.

What price target have analysts set for OMCL?

8 equities research analysts have issued 12-month price targets for Omnicell's shares. Their forecasts range from $84.00 to $188.00. On average, they anticipate Omnicell's share price to reach $138.07 in the next year. This suggests that the stock has a possible downside of 12.6%.
View analysts' price targets for Omnicell
or view top-rated stocks among Wall Street analysts.

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Randall A. Lipps, Chairman, President & Chief Executive Officer
  • Bill Wingfield, Vice President-North America Service & Operations
  • Peter J. Kuipers, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Giri Chodavarapu, Chief Information Officer
  • Scott Seidelmann, Chief Commercial Officer & Executive VP (LinkedIn Profile)

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.52%), Tributary Capital Management LLC (0.32%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%), Green Alpha Advisors LLC (0.01%) and Private Advisor Group LLC (0.01%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell

Which institutional investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, and Scout Investments Inc.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, James T Judson, Peter J Kuipers, Randall A Lipps, Robin Gene Seim, and Scott Peter Seidelmann.
View insider buying and selling activity for Omnicell
or view top insider-selling stocks.

Which institutional investors are buying Omnicell stock?

OMCL stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Private Advisor Group LLC, Louisiana State Employees Retirement System, Green Alpha Advisors LLC, Private Capital Group LLC, and Veriti Management LLC.
View insider buying and selling activity for Omnicell
or or view top insider-buying stocks.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $157.94.

How much money does Omnicell make?

Omnicell has a market capitalization of $6.87 billion and generates $892.21 million in revenue each year. The company earns $32.19 million in net income (profit) each year or $1.74 on an earnings per share basis.

How many employees does Omnicell have?

Omnicell employs 2,860 workers across the globe.

Does Omnicell have any subsidiaries?

The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.

When was Omnicell founded?

Omnicell was founded in 1992.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

Where are Omnicell's headquarters?

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at (650) 251-6100 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.